Raymond James Downgrades AMAG Pharmaceuticals (AMAG) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Leerink Partners Downgrades AMAG Pharmaceuticals (AMAG) to Market Perform
January 10, 2017 8:14 AM ESTLeerink Partners downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Outperform to Market Perform with a price target of $25.00 (from $39.00).
For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.
Shares of AMAG Pharmaceuticals closed at $23.00 yesterday.
... MoreAMAG Pharma (AMAG), Palatin (PTN) Enter Pact for NA Rights to Rekyndatm
January 9, 2017 8:07 AM ESTAMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) together with Palatin Technologies, Inc. (NYSE PTN) today announced they have entered into an agreement for exclusive North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, that has successfully completed two Phase 3 trials. The anticipated filing date in the U.S. for a new drug application (NDA) for Rekynda is in early 2018, with an anticipated approval and launch by early 2019.
AMAG is excited to expand its womens health portfolio with a... More
AMAG Pharma (AMAG) Offers Q4 and FY17 Guidance
January 9, 2017 8:05 AM ESTAMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today provided a business update, including announcing preliminary unaudited fourth quarter and annual 2016 financial results, 2017 financial guidance, and an update on its Makena® subcutaneous auto-injector program. In a separate release, the company also announced a licensing transaction for RekyndaTM (bremelanotide). The company will present further details at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2017 at 11:30 a.m. PT (2:30 p.m. ET). A live audio webcast of the presentation and the following breakout session will be accessible through the Investors section of... More
